Mike Lyman

Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.

Marian E. Gindy, J. Hochman, M. Ou, 2014, Molecular pharmaceutics.

Administration of Fenofibrate Markedly Elevates Fabp3 in Rat Liver and Plasma and Confounds Its Use as a Preclinical Biomarker of Cardiac and Muscle Toxicity.

Mike Lyman, Scott E. Fauty, K. Vlasakova, 2018, Lipids.

Reaction Phenotyping of Low-Turnover Compounds in Long-Term Hepatocyte Cultures Through Persistent Selective Inhibition of Cytochromes P450

B. Ma, D. Tweedie, Mike Lyman, 2021, Drug Metabolism and Disposition.

Development of a liver-targeted siRNA delivery platform with a broad therapeutic window utilizing biodegradable polypeptide-based polymer conjugates.

B. Carr, L. Sepp-Lorenzino, Rob S. Burke, 2014, Journal of controlled release : official journal of the Controlled Release Society.